The author examined the incidence and severity of extrapyramidal
symptoms (EPS) in 19 male psychotic outpatients receiving fluphenazine
decanoate. Ten patients developed an EPS; only 3 had symptoms of the
highest severity. The data suggest that neither prophylactic nor long- term
use of antiparkinsonian agents is necessary for most patients receiving
fluphenazine decanoate. On the basis of a comparison to a study of
fluphenazine enanthate patients, the author concludes that fluphenazine
decanoate is the drug of choice in terms of incidence and severity of
EPS.Abstract Teaser